8-K: Longboard Pharmaceuticals Acquired by H. Lundbeck A/S in $60 Per Share Deal

Longboard Pharmaceuticals has been acquired by H. Lundbeck A/S for $60 per share, completing the merger on December 2, 2024.

Summary

• Longboard Pharmaceuticals was acquired by H. Lundbeck A/S on December 2, 2024, following a successful tender offer.
• The tender offer, which expired on November 27, 2024, saw approximately 88.6% of Longboard's outstanding shares tendered at a price of $60.00 per share.
• Following the tender offer, a merger was completed, with Longboard becoming an indirect wholly-owned subsidiary of H. Lundbeck A/S.
• All outstanding shares not already tendered were converted into the right to receive $60.00 per share in cash.
• Outstanding stock options and restricted stock units were cashed out, with unvested options accelerating and becoming fully vested.
• Retention RSUs will be paid out according to their original vesting schedules.

Sentiment

Score: 8

Explanation: The document reflects a successful acquisition, which is generally positive for shareholders who received a premium for their shares. The sentiment is positive due to the completion of the deal as expected.

Positives

• Shareholders received a cash payment of $60.00 per share.
• Unvested stock options were accelerated, providing immediate value to holders.
• The acquisition provides a clear exit strategy for Longboard's investors.

Negatives

• Longboard Pharmaceuticals is no longer a publicly traded company.
• The company's equity incentive plans and employee stock purchase plan were terminated.

Risks

• There is a risk that some shareholders may not have tendered their shares and may have to go through appraisal processes.
• The company is now a wholly-owned subsidiary of H. Lundbeck A/S, which may change its strategic direction.

Future Outlook

Longboard Pharmaceuticals will operate as an indirect wholly-owned subsidiary of H. Lundbeck A/S.

Industry Context

The acquisition of Longboard Pharmaceuticals by H. Lundbeck A/S is part of the ongoing consolidation in the pharmaceutical industry, where larger companies acquire smaller firms to expand their pipelines and market presence.

Comparison to Industry Standards

• The acquisition price of $60 per share is a premium over the recent trading price of Longboard, which is typical in acquisitions.
• The tender offer process and subsequent merger are standard procedures for acquisitions of publicly traded companies.
• The cash-out of stock options and restricted stock units is a common practice in such transactions.
• Comparable acquisitions in the pharmaceutical sector often involve similar deal structures, including tender offers and subsequent mergers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received a cash payment for their shares.
• Employees may experience changes in their roles and responsibilities under the new ownership.
• Customers and suppliers may see changes in the company's operations and strategies.

Next Steps

• Longboard Pharmaceuticals will operate as a subsidiary of H. Lundbeck A/S.
• The company will file a Form 15 with the SEC to terminate its registration and reporting obligations.

Key Dates

Keywords

acquisition, merger, tender offer, pharmaceuticals, H. Lundbeck A/S, Longboard Pharmaceuticals, delisting, stock options, restricted stock units